我院2010-2013年口服降糖药应用分析  

Analysis of the Utilization of Oral Hypoglycemic Agents in Our Hospital during the Period of 2010-2013

作　　者：石卫峰[1] 夏洁[2] 傅亮[3] 归成[1] 刘皋林[1] 

机构地区：[1]上海交通大学附属第一人民医院临床药学科,上海200080 [2]大连医科大学临床药学系,辽宁大连116044 [3]上海交通大学附属第一人民医院信息科,上海200080

出　　处：《中国药房》2015年第5期596-599,共4页China Pharmacy

摘　　要：目的:为临床合理使用口服降糖药(OHAs)提供参考。方法:采用回顾性分析方法,对我院2010-2013年临床应用的OHAs品种、销售金额、用药频度(DDDs)、日均费用(DDC)等进行统计、分析。结果:我院2010-2013年OHAs的销售金额总体呈下降趋势,销售金额排序列前4位的是阿卡波糖、二甲双胍、瑞格列奈和格列美脲,其4年销售金额之和占OHAs总销售金额的67.73%;DDDs排序列前4位的依次为二甲双胍、阿卡波糖、格列齐特和瑞格列奈;格列齐特和二甲双胍的DDC均较低。二肽基肽酶-4抑制剂近两年开始进入临床,且增长快速。结论:我院OHAs的临床应用基本合理,高效、安全、依从性好的药物更受临床青睐。OBJECTIVE： To provide reference for rational use of oral hypoglycemic agents （OHAs） in the clinic. METH- ODS： By retrospective analysis, the utilization of OHAs in our hospital during the period of 2010-2013 was analyzed statistically in respect of drug categories, consumption sum, DDDs and DDC, etc. RESULTS ： The consumption sum of OHAs in our hospital during 2010-2013 is on a downward trend on the whole. The top 40HAs in the list of consumption sum were acarbose, metformin, repaglinide and glimepiride; the consumption sum of them account for 67.73%of the total in 4 years. Metformin, acarbose, gliclazide and repaglinide have ranked top 4 in terms of DDDs; gliclazide and metformin have the lower DDC. Dipeptidyl peptidase-4 inhibitors begin to be used in the clinic in nearly 2 years and are growing rapidly. CONCLUSIONS： The application of OHAs is rational basically in our hospital and the drugs with good efficacy, safety and compliance are more subject to the clinic.

关 键 词：口服降糖药 销售金额 用药频度 日均费用 用药分析 

分 类 号：R977.15[医药卫生—药品] R959[医药卫生—药学]